New combo therapy aims to beat back stubborn lymphoma before stem cell transplant
NCT ID NCT07365306
First seen Feb 01, 2026 · Last updated May 22, 2026 · Updated 11 times
Summary
This study tests a new drug combination (epcoritamab plus chemotherapy) given before a stem cell transplant for people with a type of aggressive lymphoma (DLBCL) that has come back or not responded to prior treatments. The goal is to see if this approach can completely eliminate cancer before the transplant. About 43 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Atlanta Cancer Center
NOT_YET_RECRUITINGNewnan, Georgia, 30265, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
City of Hope at Chicago
NOT_YET_RECRUITINGZion, Illinois, 60099, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.